We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Genetic Mutation Causes High Bone Density

By Biotechdaily staff writers
Posted on 29 May 2002
Researchers have discovered a genetic mutation that causes extremely high bone density in humans. More...
The finding may suggest a new route for developing drugs that can increase bone density to prevent or treat osteoporosis. The study was published in the May 16, 2002, issue of The New England Journal of Medicine.

The investigators identified a US family with very strong bones because of a genetic mutation. Family members with this mutation have no symptoms, but they do have a strikingly deep and wide jaw and bony growth on the palate. Twenty family members aided the research by providing blood samples for DNA and bone density testing. Seven members of the family had extremely high bone density, while nine had entirely normal density. Serum and urinary biochemical measurements were performed in four members and then compared with results from nine control subjects.

"What we found is that the high bone density in this family behaved as a single gene disorder,” said Richard Lifton, M.D., chair of the department of genetics at Yale School of Medicine (New Haven, CT, USA). "We then went on to map the location of the gene and identified the specific mutation responsible for the high bone density.”

The researchers mapped the gene to the same chromosome segment in LRP5, shown to be the source of a mutation that causes a loss in the function of the LRP5 gene, resulting in low bone density. "It made us wonder if a different mutation increased LRP5 function leading to an opposite phenotype, that is, high bone density,” explained Dr. Lifton. He noted that the study also showed that prevention of the normal inhibition of LRP5 by Dkk, another developmental protein, causes high bone density without other clinical side effects, suggesting a new route for osteoporosis therapy.




Related Links:
Yale Univ.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.